Medical Care
Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Research Report 2025
- May 05, 25
- ID: 226331
- Pages: 90
- Figures: 88
- Views: 38
The global market for Eosinophilic Granulomatosis with Polyangiitis Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare autoimmune disease that affects small and medium-sized blood vessels and is characterized by eosinophilic inflammation. EGPA can involve multiple organ systems, including the skin, lungs, heart, nerves, and gastrointestinal tract. Treatment for EGPA typically involves a combination of medications to suppress the immune system, manage inflammation, and alleviate specific symptoms. The choice of treatment may depend on the severity of the disease and the organs affected.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Eosinophilic Granulomatosis with Polyangiitis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eosinophilic Granulomatosis with Polyangiitis Treatment.
The Eosinophilic Granulomatosis with Polyangiitis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Eosinophilic Granulomatosis with Polyangiitis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Eosinophilic Granulomatosis with Polyangiitis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Genentech
Roche
Cephalon
Teva Pharmaceutical Industries
Amgen
Sanofi
Koninklijke DSM
AstraZeneca
Novartis
GSK
Baxter International
Segment by Type
Steroids
Immunosuppressant
Biologics
Immune Globulins
Segment by Application
Oral
Intravenous
Intramuscular
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Eosinophilic Granulomatosis with Polyangiitis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare autoimmune disease that affects small and medium-sized blood vessels and is characterized by eosinophilic inflammation. EGPA can involve multiple organ systems, including the skin, lungs, heart, nerves, and gastrointestinal tract. Treatment for EGPA typically involves a combination of medications to suppress the immune system, manage inflammation, and alleviate specific symptoms. The choice of treatment may depend on the severity of the disease and the organs affected.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Eosinophilic Granulomatosis with Polyangiitis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eosinophilic Granulomatosis with Polyangiitis Treatment.
The Eosinophilic Granulomatosis with Polyangiitis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Eosinophilic Granulomatosis with Polyangiitis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Eosinophilic Granulomatosis with Polyangiitis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Genentech
Roche
Cephalon
Teva Pharmaceutical Industries
Amgen
Sanofi
Koninklijke DSM
AstraZeneca
Novartis
GSK
Baxter International
Segment by Type
Steroids
Immunosuppressant
Biologics
Immune Globulins
Segment by Application
Oral
Intravenous
Intramuscular
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Eosinophilic Granulomatosis with Polyangiitis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Steroids
1.2.3 Immunosuppressant
1.2.4 Biologics
1.2.5 Immune Globulins
1.3 Market by Application
1.3.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Oral
1.3.3 Intravenous
1.3.4 Intramuscular
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Perspective (2020-2031)
2.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Growth Trends by Region
2.2.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Eosinophilic Granulomatosis with Polyangiitis Treatment Historic Market Size by Region (2020-2025)
2.2.3 Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Region (2026-2031)
2.3 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Dynamics
2.3.1 Eosinophilic Granulomatosis with Polyangiitis Treatment Industry Trends
2.3.2 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Drivers
2.3.3 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Challenges
2.3.4 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Players by Revenue
3.1.1 Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Players by Revenue (2020-2025)
3.1.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue
3.4 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Concentration Ratio
3.4.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in 2024
3.5 Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment Head office and Area Served
3.6 Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Product and Application
3.7 Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Eosinophilic Granulomatosis with Polyangiitis Treatment Breakdown Data by Type
4.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Historic Market Size by Type (2020-2025)
4.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Type (2026-2031)
5 Eosinophilic Granulomatosis with Polyangiitis Treatment Breakdown Data by Application
5.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Historic Market Size by Application (2020-2025)
5.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)
6.2 North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025)
6.4 North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)
7.2 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025)
7.4 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)
8.2 Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)
9.2 Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025)
9.4 Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)
10.2 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Genentech
11.1.1 Genentech Company Details
11.1.2 Genentech Business Overview
11.1.3 Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.1.4 Genentech Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.1.5 Genentech Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.2.4 Roche Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.2.5 Roche Recent Development
11.3 Cephalon
11.3.1 Cephalon Company Details
11.3.2 Cephalon Business Overview
11.3.3 Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.3.4 Cephalon Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.3.5 Cephalon Recent Development
11.4 Teva Pharmaceutical Industries
11.4.1 Teva Pharmaceutical Industries Company Details
11.4.2 Teva Pharmaceutical Industries Business Overview
11.4.3 Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.4.4 Teva Pharmaceutical Industries Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.4.5 Teva Pharmaceutical Industries Recent Development
11.5 Amgen
11.5.1 Amgen Company Details
11.5.2 Amgen Business Overview
11.5.3 Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.5.4 Amgen Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.5.5 Amgen Recent Development
11.6 Sanofi
11.6.1 Sanofi Company Details
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.6.4 Sanofi Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.6.5 Sanofi Recent Development
11.7 Koninklijke DSM
11.7.1 Koninklijke DSM Company Details
11.7.2 Koninklijke DSM Business Overview
11.7.3 Koninklijke DSM Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.7.4 Koninklijke DSM Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.7.5 Koninklijke DSM Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.8.4 AstraZeneca Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.8.5 AstraZeneca Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.9.4 Novartis Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.9.5 Novartis Recent Development
11.10 GSK
11.10.1 GSK Company Details
11.10.2 GSK Business Overview
11.10.3 GSK Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.10.4 GSK Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.10.5 GSK Recent Development
11.11 Baxter International
11.11.1 Baxter International Company Details
11.11.2 Baxter International Business Overview
11.11.3 Baxter International Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.11.4 Baxter International Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.11.5 Baxter International Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Steroids
1.2.3 Immunosuppressant
1.2.4 Biologics
1.2.5 Immune Globulins
1.3 Market by Application
1.3.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Oral
1.3.3 Intravenous
1.3.4 Intramuscular
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Perspective (2020-2031)
2.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Growth Trends by Region
2.2.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Eosinophilic Granulomatosis with Polyangiitis Treatment Historic Market Size by Region (2020-2025)
2.2.3 Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Region (2026-2031)
2.3 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Dynamics
2.3.1 Eosinophilic Granulomatosis with Polyangiitis Treatment Industry Trends
2.3.2 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Drivers
2.3.3 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Challenges
2.3.4 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Players by Revenue
3.1.1 Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Players by Revenue (2020-2025)
3.1.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue
3.4 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Concentration Ratio
3.4.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in 2024
3.5 Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment Head office and Area Served
3.6 Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Product and Application
3.7 Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Eosinophilic Granulomatosis with Polyangiitis Treatment Breakdown Data by Type
4.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Historic Market Size by Type (2020-2025)
4.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Type (2026-2031)
5 Eosinophilic Granulomatosis with Polyangiitis Treatment Breakdown Data by Application
5.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Historic Market Size by Application (2020-2025)
5.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)
6.2 North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025)
6.4 North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)
7.2 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025)
7.4 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)
8.2 Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)
9.2 Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025)
9.4 Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)
10.2 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Genentech
11.1.1 Genentech Company Details
11.1.2 Genentech Business Overview
11.1.3 Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.1.4 Genentech Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.1.5 Genentech Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.2.4 Roche Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.2.5 Roche Recent Development
11.3 Cephalon
11.3.1 Cephalon Company Details
11.3.2 Cephalon Business Overview
11.3.3 Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.3.4 Cephalon Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.3.5 Cephalon Recent Development
11.4 Teva Pharmaceutical Industries
11.4.1 Teva Pharmaceutical Industries Company Details
11.4.2 Teva Pharmaceutical Industries Business Overview
11.4.3 Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.4.4 Teva Pharmaceutical Industries Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.4.5 Teva Pharmaceutical Industries Recent Development
11.5 Amgen
11.5.1 Amgen Company Details
11.5.2 Amgen Business Overview
11.5.3 Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.5.4 Amgen Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.5.5 Amgen Recent Development
11.6 Sanofi
11.6.1 Sanofi Company Details
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.6.4 Sanofi Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.6.5 Sanofi Recent Development
11.7 Koninklijke DSM
11.7.1 Koninklijke DSM Company Details
11.7.2 Koninklijke DSM Business Overview
11.7.3 Koninklijke DSM Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.7.4 Koninklijke DSM Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.7.5 Koninklijke DSM Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.8.4 AstraZeneca Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.8.5 AstraZeneca Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.9.4 Novartis Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.9.5 Novartis Recent Development
11.10 GSK
11.10.1 GSK Company Details
11.10.2 GSK Business Overview
11.10.3 GSK Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.10.4 GSK Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.10.5 GSK Recent Development
11.11 Baxter International
11.11.1 Baxter International Company Details
11.11.2 Baxter International Business Overview
11.11.3 Baxter International Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction
11.11.4 Baxter International Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
11.11.5 Baxter International Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Steroids
Table 3. Key Players of Immunosuppressant
Table 4. Key Players of Biologics
Table 5. Key Players of Immune Globulins
Table 6. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Region (2020-2025)
Table 10. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Region (2026-2031)
Table 12. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Trends
Table 13. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Drivers
Table 14. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Challenges
Table 15. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Restraints
Table 16. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Players (2020-2025)
Table 18. Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment as of 2024)
Table 19. Ranking of Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Headquarters and Area Served
Table 22. Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Product and Application
Table 23. Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Type (2020-2025)
Table 27. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Type (2026-2031)
Table 29. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Application (2020-2025)
Table 31. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Application (2026-2031)
Table 33. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 48. Genentech Company Details
Table 49. Genentech Business Overview
Table 50. Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 51. Genentech Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 52. Genentech Recent Development
Table 53. Roche Company Details
Table 54. Roche Business Overview
Table 55. Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 56. Roche Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 57. Roche Recent Development
Table 58. Cephalon Company Details
Table 59. Cephalon Business Overview
Table 60. Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 61. Cephalon Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 62. Cephalon Recent Development
Table 63. Teva Pharmaceutical Industries Company Details
Table 64. Teva Pharmaceutical Industries Business Overview
Table 65. Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 66. Teva Pharmaceutical Industries Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 67. Teva Pharmaceutical Industries Recent Development
Table 68. Amgen Company Details
Table 69. Amgen Business Overview
Table 70. Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 71. Amgen Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 72. Amgen Recent Development
Table 73. Sanofi Company Details
Table 74. Sanofi Business Overview
Table 75. Sanofi Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 76. Sanofi Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 77. Sanofi Recent Development
Table 78. Koninklijke DSM Company Details
Table 79. Koninklijke DSM Business Overview
Table 80. Koninklijke DSM Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 81. Koninklijke DSM Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 82. Koninklijke DSM Recent Development
Table 83. AstraZeneca Company Details
Table 84. AstraZeneca Business Overview
Table 85. AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 86. AstraZeneca Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 87. AstraZeneca Recent Development
Table 88. Novartis Company Details
Table 89. Novartis Business Overview
Table 90. Novartis Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 91. Novartis Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 92. Novartis Recent Development
Table 93. GSK Company Details
Table 94. GSK Business Overview
Table 95. GSK Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 96. GSK Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 97. GSK Recent Development
Table 98. Baxter International Company Details
Table 99. Baxter International Business Overview
Table 100. Baxter International Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 101. Baxter International Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 102. Baxter International Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
Table 106. Authors List of This Report
List of Figures
Figure 1. Eosinophilic Granulomatosis with Polyangiitis Treatment Picture
Figure 2. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Type: 2024 VS 2031
Figure 4. Steroids Features
Figure 5. Immunosuppressant Features
Figure 6. Biologics Features
Figure 7. Immune Globulins Features
Figure 8. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Application: 2024 VS 2031
Figure 10. Oral Case Studies
Figure 11. Intravenous Case Studies
Figure 12. Intramuscular Case Studies
Figure 13. Eosinophilic Granulomatosis with Polyangiitis Treatment Report Years Considered
Figure 14. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Region: 2024 VS 2031
Figure 17. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Players in 2024
Figure 18. Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in 2024
Figure 20. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Country (2020-2031)
Figure 22. United States Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Country (2020-2031)
Figure 26. Germany Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Region (2020-2031)
Figure 34. China Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Country (2020-2031)
Figure 42. Mexico Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Country (2020-2031)
Figure 46. Turkey Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Genentech Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 50. Roche Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 51. Cephalon Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 52. Teva Pharmaceutical Industries Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 53. Amgen Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 54. Sanofi Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 55. Koninklijke DSM Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 56. AstraZeneca Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 57. Novartis Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 58. GSK Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 59. Baxter International Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Steroids
Table 3. Key Players of Immunosuppressant
Table 4. Key Players of Biologics
Table 5. Key Players of Immune Globulins
Table 6. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Region (2020-2025)
Table 10. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Region (2026-2031)
Table 12. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Trends
Table 13. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Drivers
Table 14. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Challenges
Table 15. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Restraints
Table 16. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Players (2020-2025)
Table 18. Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment as of 2024)
Table 19. Ranking of Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Headquarters and Area Served
Table 22. Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Product and Application
Table 23. Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Type (2020-2025)
Table 27. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Type (2026-2031)
Table 29. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Application (2020-2025)
Table 31. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Application (2026-2031)
Table 33. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 48. Genentech Company Details
Table 49. Genentech Business Overview
Table 50. Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 51. Genentech Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 52. Genentech Recent Development
Table 53. Roche Company Details
Table 54. Roche Business Overview
Table 55. Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 56. Roche Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 57. Roche Recent Development
Table 58. Cephalon Company Details
Table 59. Cephalon Business Overview
Table 60. Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 61. Cephalon Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 62. Cephalon Recent Development
Table 63. Teva Pharmaceutical Industries Company Details
Table 64. Teva Pharmaceutical Industries Business Overview
Table 65. Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 66. Teva Pharmaceutical Industries Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 67. Teva Pharmaceutical Industries Recent Development
Table 68. Amgen Company Details
Table 69. Amgen Business Overview
Table 70. Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 71. Amgen Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 72. Amgen Recent Development
Table 73. Sanofi Company Details
Table 74. Sanofi Business Overview
Table 75. Sanofi Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 76. Sanofi Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 77. Sanofi Recent Development
Table 78. Koninklijke DSM Company Details
Table 79. Koninklijke DSM Business Overview
Table 80. Koninklijke DSM Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 81. Koninklijke DSM Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 82. Koninklijke DSM Recent Development
Table 83. AstraZeneca Company Details
Table 84. AstraZeneca Business Overview
Table 85. AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 86. AstraZeneca Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 87. AstraZeneca Recent Development
Table 88. Novartis Company Details
Table 89. Novartis Business Overview
Table 90. Novartis Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 91. Novartis Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 92. Novartis Recent Development
Table 93. GSK Company Details
Table 94. GSK Business Overview
Table 95. GSK Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 96. GSK Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 97. GSK Recent Development
Table 98. Baxter International Company Details
Table 99. Baxter International Business Overview
Table 100. Baxter International Eosinophilic Granulomatosis with Polyangiitis Treatment Product
Table 101. Baxter International Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)
Table 102. Baxter International Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
Table 106. Authors List of This Report
List of Figures
Figure 1. Eosinophilic Granulomatosis with Polyangiitis Treatment Picture
Figure 2. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Type: 2024 VS 2031
Figure 4. Steroids Features
Figure 5. Immunosuppressant Features
Figure 6. Biologics Features
Figure 7. Immune Globulins Features
Figure 8. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Application: 2024 VS 2031
Figure 10. Oral Case Studies
Figure 11. Intravenous Case Studies
Figure 12. Intramuscular Case Studies
Figure 13. Eosinophilic Granulomatosis with Polyangiitis Treatment Report Years Considered
Figure 14. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Region: 2024 VS 2031
Figure 17. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Players in 2024
Figure 18. Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in 2024
Figure 20. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Country (2020-2031)
Figure 22. United States Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Country (2020-2031)
Figure 26. Germany Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Region (2020-2031)
Figure 34. China Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Country (2020-2031)
Figure 42. Mexico Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Country (2020-2031)
Figure 46. Turkey Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Genentech Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 50. Roche Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 51. Cephalon Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 52. Teva Pharmaceutical Industries Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 53. Amgen Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 54. Sanofi Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 55. Koninklijke DSM Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 56. AstraZeneca Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 57. Novartis Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 58. GSK Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 59. Baxter International Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Potassium Bromide Windows Market Research Report 2025
Dec 14, 25
Global Bio-based 1,10-Decanediol Diacrylate Market Research Report 2025
Dec 14, 25
Global Bio-based 1,5-Pentanediol Diacrylate(PDDA) Market Research Report 2025
Dec 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232